Syndax's Revuforj Data Signals a Strategic Shift in AML Treatment

NEW YORK, June 11, 2026 -- In a significant development for oncology, Syndax Pharmaceuticals today announced striking new data for its menin inhibitor, Revuforj® (revumenib). The results from the Phase 1/2 SAVE trial, evaluating an all-oral combination therapy for relapsed or refractory (R/R) acute myeloid leukemia (AML), were simultaneously published in the prestigious Journal of Clinical Oncology and presented at the European Hematology Association (EHA) 2026 Congress. The findings reveal a potent new weapon against specific, hard-to-treat forms of leukemia, signaling not only a potential paradigm shift in patient care but also a major strategic victory for the biopharmaceutical company.

For a patient population facing a grim prognosis—where median survival after failing standard therapies can be measured in mere months—the SAVE trial data offers a powerful dose of optimism. The all-oral regimen, combining Revuforj with decitabine/cedazuridine and the established AML drug venetoclax, demonstrated an impressive 88% overall response rate (ORR) and a 71% composite complete remission (CRc) rate in a heavily pretreated group of patients. These are individuals for whom prior treatments, including intensive chemotherapy and even stem cell transplants, had failed.

Redefining Outcomes in a High-Unmet Need

The true measure of an anti-cancer therapy lies not just in its ability to shrink tumors, but in the depth and durability of that response. Here, the SAVE trial results are particularly compelling. A remarkable 80% of patients who achieved a composite complete remission were also found to be free of measurable residual disease (MRD), a highly sensitive measure indicating a profound clearance of leukemia cells. Achieving MRD negativity is a critical benchmark that strongly correlates with longer-term survival and a lower risk of relapse.

“The results observed with the all-oral SAVE regimen in heavily pretreated patients with R/R NPM1m, KMT2Ar, or NUP98r AML are very encouraging,” said Dr. Ghayas C. Issa, the trial's principal investigator from The University of Texas MD Anderson Cancer Center. He highlighted a key subgroup: patients who had already been treated with and failed venetoclax, a BCL-2 inhibitor that has become a cornerstone of AML therapy. This population has historically faced an exceptionally poor prognosis, with median survival often less than three months. In the SAVE trial, these patients achieved an impressive 50% CR/CRh rate (complete remission or complete remission with partial hematological recovery) and a median overall survival of approximately 12 months. This finding suggests the combination may overcome or reverse prior treatment resistance, a holy grail in oncology.

The data also underscores the regimen's potential as a crucial bridge to a definitive cure. Allogeneic hematopoietic stem cell transplant (HSCT) remains the only curative option for most R/R AML patients, but many are too sick to undergo the procedure. The Revuforj combination enabled 45% of trial participants to proceed to transplant. Tellingly, 63% of those patients resumed revumenib after their transplant, suggesting a potential new role for the drug in maintaining remission long-term.

The Strategic Science of Combination Therapy

Revuforj is the first and only FDA-approved menin inhibitor, a novel class of drugs that targets the underlying drivers of specific AML subtypes. It works by disrupting a critical protein interaction involving menin that fuels the growth of leukemias with NPM1 mutations or KMT2A rearrangements. Rather than being a blunt instrument, it is a precision tool designed for a specific biological vulnerability.

The success of the SAVE trial lies in its strategic combination. By pairing the targeted action of revumenib with venetoclax and a hypomethylating agent (decitabine/cedazuridine), the regimen attacks the cancer from multiple angles. Dr. Issa noted this supports a “potential biologic synergy between BCL2 inhibition and menin inhibition,” a concept that could reshape future treatment protocols. The implication is that menin inhibition may not only work on its own but could also restore sensitivity to other proven therapies once resistance has developed.

This all-oral regimen also represents a significant improvement in quality of life. For patients who have already endured rounds of grueling intravenous chemotherapy, the ability to take effective medication at home is a transformative shift, reducing the burden of hospital visits and empowering patients in their own care. While the combination was generally well-tolerated, Syndax is transparent about the risks, which include a boxed warning for Differentiation Syndrome and QTc Prolongation, underscoring the need for careful patient monitoring by specialists.

Cementing a Competitive Advantage

The SAVE data does more than just validate Revuforj's clinical utility; it significantly strengthens Syndax's strategic position in the competitive oncology market. As the first company to bring a menin inhibitor to market, Syndax already holds a valuable first-mover advantage. This robust combination data solidifies that lead and provides a powerful counter-narrative to other menin inhibitors in development, such as ziftomenib from Kura Oncology.

“The SAVE data provide strong support for further studying revumenib with venetoclax and a hypomethylating agent in multiple settings,” stated Nick Botwood, Syndax's Head of Research & Development. This points directly to the company's forward-looking strategy: moving Revuforj from a therapy for relapsed patients into the frontline setting. The company is already enrolling patients in the pivotal EVOLVE-2 trial for newly diagnosed patients and the RAVEN trial to explore further combinations.

Success in these earlier settings would dramatically expand Revuforj’s market potential, positioning it as a foundational therapy for all patients with menin-dependent leukemias. This pipeline progression, coupled with the company’s second approved asset, Niktimvo™ for chronic graft-versus-host disease, showcases Syndax’s evolution into a mature, commercial-stage biopharmaceutical entity capable of navigating the full drug development and commercialization lifecycle. For investors and industry observers, these results serve as a powerful de-risking event, validating the science behind menin inhibition and Syndax's ability to execute a complex clinical and commercial strategy in a landscape defined by rapid innovation.